|
Inflammation, Infection, and Future Cardiovascular Risk Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Inflammation, Infection, and Future Cardiovascular Risk conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Inflammation, Infection, and Future Cardiovascular Risk Clinical research trials and Inflammation, Infection, and Future Cardiovascular Risk healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Inflammation, Infection, and Future Cardiovascular Risk. Inflammation, Infection, and Future Cardiovascular Risk Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Inflammation, Infection, and Future Cardiovascular Risk clinical trial. Human subjects often obtain the finest healthcare possible for their Inflammation, Infection, and Future Cardiovascular Risk condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Inflammation, Infection, and Future Cardiovascular Risk  Inflammation, Infection, and Future Cardiovascular Risk
Inflammation, Infection, and Future Cardiovascular Risk
For Condition: Herpesviridae Infections,Inflammation,Infection,Coronary Disease,Chlamydia Infections,Cerebrovascular Accident,Heart Diseases,Myocardial Infarction,Cardiovascular Diseases,Helicobacter Infections,Venous Thromboembolism,Cytomegalovirus Infections
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To examine markers of underlying chronic inflammation and infection as potential risk factors for future myocardial infarction (MI), stroke (CVA), and venous thromboembolism (VTE) in plasma samples collected at baseline from healthy participants in the Physicians' Health Study (PHS).
Details: BACKGROUND: The PHS is a cohort which included 14,916 men initially free of cardiovascular disease and cancer who provided plasma samples at study entry in 1982. These men were randomly assigned in a factorial design to aspirin or beta-carotene therapy, and have been followed prospectively for the occurrence of vascular disease. DESIGN NARRATIVE: Employing a nested case-control design, baseline plasma samples are assayed for four markers of inflammation (interleukin-6, TNF-alpha, soluble ICAM, soluble VCAM) and four markers of chronic infection (antibody titers directed against Chlamydia pneumoniae, Helicobacter pylori, Herpes simplex virus, and cytomegalovirus). Case subjects are those study participants who have subsequently developed MI (N=550), CVA (N=400), or VTE (N=200). Control subjects are selected from those study participants who remained healthy during follow-up and are matched to the cases by age, smoking status, and follow-up time. Data on usual cardiovascular risk factors, lipid parameters, and hemostatic markers of risk are already available in the PHS and will be used to evaluate the results for potential confounding and effect modification. Since the PHS was a randomized trial of low-dose aspirin for its initial 5 years, this cohort also provides the unique opportunity to investigate whether the use of an agent with anti-inflammatory properties modifies the risk of subsequent thrombosis among those with underlying inflammation. Indeed, this intriguing hypothesis has recently been raised regarding data relating another marker of inflammation, C-reactive protein, to future risks of myocardial infarction and stroke. These analyses will take advantage of an existing blood bank from a well-characterized large cohort with many years of follow-up and high quality end-point verification. Thus, this study could provide an efficient and cost-effective mechanism to evaluate the posited, but unproven roles of inflammation and infection as risk factors for future cardiovascular disease.
Eligibility:
Study Type: Observational, Natural History, Case Control
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PaulRidker, , Brigham and Women's Hospital
Additional Information:
Study ID Numbers: 5014;
Study Start Date: September 1998
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005496
Other Infection Studies:
1. Inflammation, Infection, and Future Cardiovascular Risk
2. Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction
3. Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA
4. Cyclosporin Implant to Treat Uveitis
5. Analysis of Bronchial Tissue and Fluid in Patients with Wegener's Granulomatosis
Related Studies:
Other Infection Clinical Trials
Other Clinical Trials
Other Clinical Trials
Inflammation, Infection, and Future Cardiovascular Risk
|
|
|
|
|
|
|
|
